Keros Therapeutics (KROS) News Today $15.80 +0.25 (+1.61%) Closing price 04:00 PM EasternExtended Trading$15.78 -0.02 (-0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Goldman Sachs Group Inc. Boosts Position in Keros Therapeutics, Inc. $KROSSeptember 16 at 4:10 AM | marketbeat.comKeros Therapeutics presents additional clinical data from KER-065 programSeptember 9, 2025 | msn.comKeros Therapeutics Presents Promising Phase 1 Trial DataSeptember 9, 2025 | msn.comCubist Systematic Strategies LLC Has $2.02 Million Position in Keros Therapeutics, Inc. $KROSSeptember 9, 2025 | marketbeat.comKeros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual MeetingSeptember 8, 2025 | globenewswire.comParkman Healthcare Partners LLC Lowers Stock Holdings in Keros Therapeutics, Inc. $KROSSeptember 8, 2025 | marketbeat.comInvesco Ltd. Grows Stock Position in Keros Therapeutics, Inc. $KROSSeptember 8, 2025 | marketbeat.comKeros Therapeutics, Inc. $KROS Shares Sold by Russell Investments Group Ltd.September 6, 2025 | marketbeat.comADAR1 Capital Management LLC Has $15.15 Million Holdings in Keros Therapeutics, Inc. $KROSSeptember 4, 2025 | marketbeat.comAlkeon Capital Management LLC Reduces Holdings in Keros Therapeutics, Inc. $KROSSeptember 4, 2025 | marketbeat.comPDT Partners LLC Makes New $2.81 Million Investment in Keros Therapeutics, Inc. $KROSSeptember 4, 2025 | marketbeat.comDRW Securities LLC Takes Position in Keros Therapeutics, Inc. $KROSSeptember 2, 2025 | marketbeat.comWalleye Capital LLC Reduces Holdings in Keros Therapeutics, Inc. $KROSSeptember 1, 2025 | marketbeat.com103,826 Shares in Keros Therapeutics, Inc. $KROS Bought by Jump Financial LLCSeptember 1, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Sells 37,759 Shares of Keros Therapeutics, Inc. $KROSSeptember 1, 2025 | marketbeat.comVanguard Group Inc. Purchases 609,212 Shares of Keros Therapeutics, Inc. $KROSAugust 31, 2025 | marketbeat.comCan Keros Therapeutics, Inc. (NASDAQ:KROS) Performance Keep Up Given Its Mixed Bag Of Fundamentals?August 30, 2025 | finance.yahoo.comKeros Therapeutics Announces Participation at Upcoming Healthcare ConferencesAugust 28, 2025 | globenewswire.comStonepine Capital Management LLC Buys New Holdings in Keros Therapeutics, Inc. $KROSAugust 26, 2025 | marketbeat.com22NW LP Purchases Shares of 179,000 Keros Therapeutics, Inc. $KROSAugust 26, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from BrokeragesAugust 26, 2025 | marketbeat.comADAR1 Capital sends letter to Keros Therapeutics urging board changesAugust 23, 2025 | msn.comKeros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right PathAugust 21, 2025 | seekingalpha.comKeros Therapeutics, Inc.: Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular DystrophyAugust 21, 2025 | finanznachrichten.deADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board RefreshmentAugust 21, 2025 | prnewswire.comKeros Therapeutics granted Orphan Drug designation for KER-065 in DMDAugust 21, 2025 | msn.comKeros Therapeutics Receives FDA Orphan Drug Designation for KER-065 in Duchenne Muscular Dystrophy TreatmentAugust 20, 2025 | quiverquant.comQKeros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular DystrophyAugust 20, 2025 | globenewswire.comKeros Therapeutics’ treatment of Duchenne MD granted FDA orphan designationAugust 19, 2025 | msn.comConnor Clark & Lunn Investment Management Ltd. Has $1.31 Million Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)August 18, 2025 | marketbeat.com40,245 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Purchased by Tejara Capital LtdAugust 17, 2025 | marketbeat.comKeros Therapeutics Announces Strategic Realignment and Leadership ChangesAugust 15, 2025 | theglobeandmail.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: AMN Healthcare Services (AMN), Keros Therapeutics (KROS) and Evolent Health (EVH)August 11, 2025 | theglobeandmail.comLeerink Partnrs Has Negative Estimate for KROS Q3 EarningsAugust 11, 2025 | marketbeat.comWilliam Blair Predicts Lower Earnings for Keros TherapeuticsAugust 11, 2025 | marketbeat.comHC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00August 9, 2025 | marketbeat.comXTX Topco Ltd Acquires New Position in Keros Therapeutics, Inc. (NASDAQ:KROS)August 9, 2025 | marketbeat.comKeros to Exclusively Prioritize the Clinical Advancement of KER-065August 6, 2025 | globenewswire.comKeros Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comFederated Hermes Inc. Grows Position in Keros Therapeutics, Inc. (NASDAQ:KROS)August 3, 2025 | marketbeat.comKeros Therapeutics (KROS) Projected to Post Earnings on WednesdayJuly 31, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 31, 2025 | marketbeat.comCorton Capital Inc. Makes New $186,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS)July 28, 2025 | marketbeat.comKeros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of ElriterceptJuly 17, 2025 | globenewswire.comB of A Securities Downgrades Keros Therapeutics (KROS)June 11, 2025 | msn.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 11, 2025 | marketbeat.comKeros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: AnalystJune 10, 2025 | uk.finance.yahoo.com3KROS : Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline...June 10, 2025 | benzinga.comKeros Therapeutics (NASDAQ:KROS) Rating Lowered to "Neutral" at Bank of AmericaJune 10, 2025 | marketbeat.comKeros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to StockholdersJune 9, 2025 | finanznachrichten.de Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KROS Media Mentions By Week KROS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼1.240.92▲Average Medical News Sentiment KROS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼46▲KROS Articles Average Week Get the Latest News and Ratings for KROS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Keros Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Alvotech News Tarsus Pharmaceuticals News Catalyst Pharmaceuticals News CG Oncology News ImmunityBio News IDEAYA Biosciences News Ocular Therapeutix News Denali Therapeutics News Centessa Pharmaceuticals News Mineralys Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KROS) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KROS Stock Alerts